Orchestra BioMed Holdings stock
OBIONASDAQOrchestra BioMed Holdings, Inc., HealthcareISIN US68572M1062
50Score 50 out of 100, Neutral
Price and trend
88 / 100
Price history
+39% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 33% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 3.1% below its 52-week high. Largest decline in 6 years: 89% (April 2023 to September 2025).
Chart figures for advanced users
- SMA 50$5.81
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.61
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.49
- The lowest closing price of the last twelve months.
- Resistance$6.35
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Orchestra BioMed Holdings, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $369.65M, is number 269 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $33.48M (up 1,169.2% year on year) and a loss of $52.7M.
- MEQIRI Score 50 out of 100 (Neutral): rank 377 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 42.5% a year since 2020, Biotechnology median 19.4%.Growth 70
- More cash than debtCash $106.51M, financial debt $15.96M (fiscal 2025).Stability 52
Weaknesses
- DilutionShare count up 133% since 2020.Capital allocation 18
- Loss-makingLoss of $57.82M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$64.18M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 49 to 50.
One-off effect in revenue
In the quarter to 31 Dec 2025, revenue of $30.92M was about 57 times the usual level. P/E, margin, growth and score for the last twelve months depend on it.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue fell 89.4% on the same quarter a year earlier. Revenue swung sharply, with 1 of 6 years negative.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 99%, operating −155%, net −157%. Last 12 months: net −100%.
Debt & balance sheet
Fiscal 2025Debt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Mar 2027in 118 days
- Last reported
- 10 Nov 2026EPS reported −$0.30 (expected −$0.40)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.520.0%
- Revenue
- $454K0.0%
- Earnings per share
- −$1.510.0%
- Revenue
- $577.29K0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
3 insiders bought on the open market between 14 May 2026 and 1 Jun 2026, $158,081 in total. One insider sold, $439,050 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Not counted: 5 purchases under a fixed plan (compensation, savings plan or a pre-arranged Rule 10b5-1 trading plan).
- Rtw Investments, LpPlan purchase
9 Nov 2026, Major holder
- Shares
- 1,200,000
- Price
- $5.00
- Value
- $6M
- Fain Eric SPlan purchase
9 Nov 2026, Board
- Shares
- 20,000
- Price
- $5.00
- Value
- $100,000
- Pacitti DavidPlan purchase
9 Nov 2026, Board
- Shares
- 20,000
- Price
- $5.00
- Value
- $100,000
Show 15 more
- Hochman David PPlan purchase
9 Nov 2026, See Remarks
- Shares
- 5,000
- Price
- $5.00
- Value
- $25,000
- Taylor Andrew LawrencePlan purchase
9 Nov 2026, Chief Financial Officer
- Shares
- 1,000
- Price
- $5.00
- Value
- $5,000
- Sherman DarrenSale
2 Nov 2026, See Remarks
- Shares
- 15,000
- Price
- $5.74
- Value
- $86,100
- Sherman DarrenSale
1 Oct 2026, See Remarks
- Shares
- 15,000
- Price
- $6.36
- Value
- $95,400
- Hochman David PPurchase
3 Sept 2026, See Remarks
- Shares
- 10,000
- Price
- $4.79
- Value
- $47,900
- Sherman DarrenSale
1 Sept 2026, See Remarks
- Shares
- 15,000
- Price
- $4.94
- Value
- $74,100
- Sherman DarrenPurchase
26 Aug 2026, See Remarks
- Shares
- 2,000
- Price
- $5.33
- Value
- $10,660
- Sherman DarrenSale
3 Aug 2026, See Remarks
- Shares
- 15,000
- Price
- $4.09
- Value
- $61,350
- Sherman DarrenSale
1 Jul 2026, See Remarks
- Shares
- 15,000
- Price
- $4.27
- Value
- $64,050
- Hochman David PPurchase
1 Jun 2026, See Remarks
- Shares
- 5,000
- Price
- $3.83
- Value
- $19,150
- Sherman DarrenSale
1 Jun 2026, See Remarks
- Shares
- 15,000
- Price
- $3.87
- Value
- $58,050
- Aryeh JasonPurchase
18 May 2026, Board
- Shares
- 665
- Price
- $3.75
- Value
- $2,494
- Aryeh JasonPurchase
15 May 2026, Board
- Shares
- 8,971
- Price
- $3.90
- Value
- $34,987
- Hochman David PPurchase
15 May 2026, See Remarks
- Shares
- 5,000
- Price
- $3.77
- Value
- $18,850
- Fain Eric SPurchase
14 May 2026, Board
- Shares
- 20,000
- Price
- $4.13
- Value
- $82,600
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Orchestra BioMed Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Fennec PharmaceuticalsFENC $382.23M56
- NeurogeneNGNE $377.68M32
- CorMedixCRMD $377.25M56
- Contineum TherapeuticsCTNM $375.46M35
- YD BioYDES $368.32M36
- AlectorALEC $364.75M71
- C4 TherapeuticsCCCC $363.75M34
- Sagimet BiosciencesSGMT $356.12M45
ETFs that hold Orchestra BioMed Holdings
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.02% | 0.35% | €1.25B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Weak
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.